2009-02-05 / Local & State

Enters Guilty Plea In Zyprexa Drug Case

PHILADELPHIA (AP) - The U.S. Attorney's Office for the Eastern District of Pennsylvania says drugmaker Eli Lilly & Co. formally pleaded guilty to a misdemeanor tied to the marketing of its top-seller, the antipsychotic Zyprexa.

A statement from the office says Indianapolis-based Lilly pleaded guilty to introducing misbranded drugs into interstate commerce. The company must pay a fine and forfeiture totaling $615 million.

Lilly agreed to the plea earlier this month and will pay about $800 million to resolve a civil case tied to the drug's marketing.

Prosecutors say Lilly sold Zyprexa to treat Alzheimer's-related dementia and depression, among other unapproved uses. Regulators have approved marketing of it to treat schizophrenia and bipolar disorder.

Return to top